379 related articles for article (PubMed ID: 30485606)
1. Toward the development of true "off-the-shelf" synthetic T-cell immunotherapy.
Iriguchi S; Kaneko S
Cancer Sci; 2019 Jan; 110(1):16-22. PubMed ID: 30485606
[TBL] [Abstract][Full Text] [Related]
2. New cell sources for T cell engineering and adoptive immunotherapy.
Themeli M; Rivière I; Sadelain M
Cell Stem Cell; 2015 Apr; 16(4):357-66. PubMed ID: 25842976
[TBL] [Abstract][Full Text] [Related]
3. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
Sadeqi Nezhad M; Abdollahpour-Alitappeh M; Rezaei B; Yazdanifar M; Seifalian AM
Pharm Res; 2021 Jun; 38(6):931-945. PubMed ID: 34114161
[TBL] [Abstract][Full Text] [Related]
4. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Differentiation of T Cell: From CAR-Modified T-iPSC.
Ueda T; Kaneko S
Methods Mol Biol; 2019; 2048():85-91. PubMed ID: 31396933
[TBL] [Abstract][Full Text] [Related]
6. Advances in Adoptive Cell Therapy Using Induced Pluripotent Stem Cell-Derived T Cells.
Netsrithong R; Wattanapanitch M
Front Immunol; 2021; 12():759558. PubMed ID: 34650571
[TBL] [Abstract][Full Text] [Related]
7. Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges.
Nianias A; Themeli M
Curr Hematol Malig Rep; 2019 Aug; 14(4):261-268. PubMed ID: 31243643
[TBL] [Abstract][Full Text] [Related]
8. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy.
Iriguchi S; Yasui Y; Kawai Y; Arima S; Kunitomo M; Sato T; Ueda T; Minagawa A; Mishima Y; Yanagawa N; Baba Y; Miyake Y; Nakayama K; Takiguchi M; Shinohara T; Nakatsura T; Yasukawa M; Kassai Y; Hayashi A; Kaneko S
Nat Commun; 2021 Jan; 12(1):430. PubMed ID: 33462228
[TBL] [Abstract][Full Text] [Related]
9. Adoptive Immunotherapy: A Human Pluripotent Stem Cell Perspective.
Jin G; Chang Y; Harris JD; Bao X
Cells Tissues Organs; 2023; 212(5):439-467. PubMed ID: 36599319
[TBL] [Abstract][Full Text] [Related]
10. Rise of iPSCs as a cell source for adoptive immunotherapy.
Minagawa A; Kaneko S
Hum Cell; 2014 Apr; 27(2):47-50. PubMed ID: 24510519
[TBL] [Abstract][Full Text] [Related]
11. CAR T cell immunotherapy for human cancer.
June CH; O'Connor RS; Kawalekar OU; Ghassemi S; Milone MC
Science; 2018 Mar; 359(6382):1361-1365. PubMed ID: 29567707
[TBL] [Abstract][Full Text] [Related]
12. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
[TBL] [Abstract][Full Text] [Related]
13. Cloning and expansion of antigen-specific T cells using iPS cell technology: development of "off-the-shelf" T cells for the use in allogeneic transfusion settings.
Kawamoto H; Masuda K; Nagano S; Maeda T
Int J Hematol; 2018 Mar; 107(3):271-277. PubMed ID: 29388165
[TBL] [Abstract][Full Text] [Related]
14. Adoptive T-cell therapy for cancer: The era of engineered T cells.
Bonini C; Mondino A
Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
[TBL] [Abstract][Full Text] [Related]
15. Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic.
Zhang X; Luo M; Dastagir SR; Nixon M; Khamhoung A; Schmidt A; Lee A; Subbiah N; McLaughlin DC; Moore CL; Gribble M; Bayhi N; Amin V; Pepi R; Pawar S; Lyford TJ; Soman V; Mellen J; Carpenter CL; Turka LA; Wickham TJ; Chen TF
Nat Commun; 2021 May; 12(1):2637. PubMed ID: 33976146
[TBL] [Abstract][Full Text] [Related]
16. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
17. 'Off-the-shelf' immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes.
Ando M; Nakauchi H
Exp Hematol; 2017 Mar; 47():2-12. PubMed ID: 27826124
[TBL] [Abstract][Full Text] [Related]
18. Advancing cell-based cancer immunotherapy through stem cell engineering.
Li YR; Dunn ZS; Yu Y; Li M; Wang P; Yang L
Cell Stem Cell; 2023 May; 30(5):592-610. PubMed ID: 36948187
[TBL] [Abstract][Full Text] [Related]
19. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.
Kalos M; June CH
Immunity; 2013 Jul; 39(1):49-60. PubMed ID: 23890063
[TBL] [Abstract][Full Text] [Related]
20. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
